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Abstract
Background: During Flotation-REST a person is floating inside a quiet and dark tank, filled with heated salt
saturated water. Deep relaxation and beneficial effects on e.g. stress, sleep difficulties, anxiety and depression have
been documented in earlier research. Despite that treatments for generalized anxiety disorder (GAD) are effective; it
is till the least successfully treated anxiety disorder, indicating that treatment protocols can be enhanced. The use
of Flotation-REST as a treatment of GAD has not been researched. The aim of the present study was to conduct an
initial evaluation of the effects in a self-diagnosed GAD sample.
Methods: This study was a randomized, parallel group, non-blinded trial with 1:1 allocation ratio to waiting list
control group (n = 25) or to a twelve session treatment with flotation-REST (n = 25). Inclusion criteria’s were: 18–65
years and GAD (as defined by self-report measures). The primary outcome was GAD-symptomatology, and secondary
outcomes were depression, sleep difficulties, emotion regulation difficulties and mindfulness. Assessments were made
at three time points (baseline, four weeks in treatment, post-treatment), and at six-month follow-up. The main data
analyses were conducted with a two-way MANOVA and additional t-tests. Forty-six participants (treatment, n = 24;
control, n = 22) were included in the analyses.
Results: A significant Time x Group interaction effect for GAD-symptomatology [F(2,88) = 2.93, p < .001, ηp2 = .062] was
found. Further analyses showed that the GAD-symptomatology was significantly reduced for the treatment group
(t(23) = 4.47, p < .001), but not for the waiting list control group (t(21) = 0.98, p > .05), when comparing baseline to
post-treatment scoring. Regarding clinical significant change, 37 % in the treatment group reached full remission
at post-treatment. Significant beneficial effects were also found for sleep difficulties, difficulties in emotional regulation,
and depression, while the treatment had ambiguous or non-existent effects on pathological worry and mindfulness. All
improved outcome variables at post-treatment, except for depression, were maintained at 6-months follow. No negative
effects were found.
Conclusion: The findings suggest that the method has potential as a complementary treatment alongside existing
treatment for GAD. More studies are warranted to further evaluate the treatments efficacy.
Trial registration: Australian New Zealand Clinical Trial Registry: ACTRN12613001105730, Date of registration: 03/10/2013
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Background
Generalized Anxiety Disorder (GAD) is characterized by
a more or less constant state of excessive worry and anx-
iety, with symptoms such as poor sleep, muscle tension,
irritability, and fatigue [1]. GAD is a relatively common
disorder, with a lifetime prevalence rating of 5.7 %, and a
12-month prevalence of 3.1 % [2]. It has been associated
with considerable suffering and functional impairment,
as well as high costs for society [3]. In addition, GAD is
associated with high risk of comorbidity, in which
depression is the most common secondary diagnosis [4].
Several risk factors for developing GAD have been pro-
posed, such as traumas [5], innate emotional responsive-
ness [6], dysfunctional interpersonal processes [7], as
well as insecure attachment style [8].
Although pharmacological treatment has been shown to
be effective for treating GAD [(e. g.) [9]], psychotherapies
are usually preferred over medication by patients and cli-
nicians alike [3]. Several psychotherapeutic interventions
for GAD have been developed and most of them are based
on cognitive behavioral therapy (CBT) [10]. Many of the
contemporary CBT conceptualizations of GAD propose
that the core problem in the disorder is worry, which
serves as an avoidance strategy of internal experiences,
while others emphasize difficulties in emotion regulation
as the central problem [11]. In addition, low levels of trait
mindfulness have been proposed to play an important role
in the psychopathology of GAD [12]. This is supported by
clinical studies where mindfulness training has proven to
be a robust intervention to reduce anxiety symptoms [13]
as well as by being applied successfully as a primary treat-
ment for GAD [14].
Although CBT is to be considered an effective method
for treating GAD, it is not as effective as for other types of
anxiety disorders [15]. It has also been pointed out that
the majority of treated GAD patients only reach partial re-
mission, which further highlights that many of those
which respond to treatment still have residual symptoms
[16]. Taken together this suggest that treatment protocols
might be improved, by for example adding some form of
complementary treatment. In addition, it could be valu-
able to evaluate alternative forms of treatment for GAD,
since some patients prefer complementary and alternative
medicine (CAM) to conventional interventions or use it
alongside first-line treatments [17].
The present study evaluates a CAM therapy, namely
flotation-REST (Restricted Environmental Stimulation
Technique) as an intervention for a self-diagnosed GAD-
sample. Flotation-REST has to date not been studied pri-
marily as an intervention for GAD, but the method has in
earlier research been shown to reduce stress [18], anxiety
[(e. g.) [19]] and depression [(e. g.) [20, 21]], as well as to
alleviate many of the symptoms associated with GAD,
such as sleep difficulties [22, 23], fatigue [(e. g.) [20], and
muscle tension pains [(e. g.) [24]]. During flotation-REST
a person is lying horizontally, face up, inside a quiet and
dark tank, filled with salt (magnesium sulphate) saturated
water held at 35 °C (95 F). The water has high buoyancy,
which makes it possible to float comfortably on the back
inside of the tank. It has been suggested that the method
achieves its beneficial effects through deep relaxation that
is induced by sensory isolation, and effects of treatment
are manifested without much effort or specific instruc-
tions [25]. Contemporary research on flotation-REST has
established a treatment protocol consisting of 12 sessions
(á 45 min) twice a week, which has been suggested to be
sufficient to reach the desired therapeutic effects [21].
Flotation-REST has also been used successfully as a treat-
ment for chronic pain conditions [24, 26], burn-out syn-
drome [20, 23], as well as a preventive health-care
intervention [19]. There are also pilot studies showing
promising results when flotation-REST is combined with
psychotherapy [27, 28]. Taken together earlier research in-
dicate that flotation-REST might have potential as an
complementary or alternative intervention for GAD, but
due to the focus and methodological shortcomings in earl-
ier studies further research need to establish the effective-
ness of flotation-REST as treatment for GAD. As a first
step to clarify this the present study aims to conduct an
initial evaluation to gather information which could guide
further research in the field, and answer the question if it
could be fruitful to study flotation-REST as a treatment
for GAD. The main aim of the study was to evaluate a 12
session treatment program of flotation-REST on suggested
core problems (pathological worry; emotional regulation
difficulties; and low mindfulness), the most common
secondary diagnosis (depression), as well as the symptom-
atology (e. g. fatigue, sleep-difficulties, muscle tension)
associated with GAD. The primary outcome in this study
was the general level of GAD-symptomatology, and the
secondary outcomes were depression, sleep difficulties,
emotion regulation difficulties and mindfulness. In
addition, deviation from normal state during the flotation
session was measured to assess level of subjective relax-
ation during the flotation sessions.
Method
Participants
Fifty-nine participants were recruited to the study. Re-
cruitment was made through outpatient psychiatric care,
as well as by advertisement in a local paper, stating that
sufferers of prolonged anxiety problems, and with an age
of 18–65 years, were welcomed to register their interest
to participate in a study on relaxation in flotation tank.
All recruitment was made from October 2013 to April
2014. Interested individuals who by telephone contact
seemed fitting to participate (n = 59), were screened with
the Generalized Anxiety Questionnaire 4th edition
Jonsson and Kjellgren BMC Complementary and Alternative Medicine  (2016) 16:108 Page 2 of 12
(GAD-Q-IV) and the Penn State Worry Questionnaire
(PSWQ) using a cut-off score found to successfully detect
generalized anxiety disorder (GAD) in both clinical and
non-clinical samples [29, 30]. From the recruited sample
(n = 59), in total fifty met the inclusion criteria’s and were
randomized to either treatment condition (n = 25) or
waiting-list control condition (n = 25). The randomization
was conducted by the researchers, who asked the partici-
pants to take a slip of paper from a jar. The jar contained
50 paper slips numbered from 1 to 50, where odd num-
bers indicated an allocation to treatment condition and
even numbers allocation to waiting list control condition.
Allocation was performed after the baseline assessments
were made. One participant in the treatment condition
and three participants in the waiting list condition did not
complete the study due to unknown reasons. In addition,
five participants in the treatment condition did not
complete the six-month follow-up assessments. Inclusion
criteria’s for the present study were (a) 18–65 year of age,
(b) having GAD as defined with the PSWQ (Cutoff = 45+)
and/or the GAD-Q-IV (Cutoff = 5.7+). Exclusion criteria’s
were (a) ongoing pregnancy, (b) having a pacemaker
implant, (c) having open wounds or skin-disease, (d) epi-
lepsy, (e) history of psychosis, (f) bipolar syndrome, (g)
post-traumatic stress disorder, (h) and ongoing substance
abuse (exception was made for tobacco).
Independent t-tests of the baseline assessments (See
Measures) did not indicate any significant differences
between the groups at baseline (ps > .05), except for
mindfulness (MAAS), where the waiting list control
group scored significantly higher than the treatment
group (p < .05). Although the groups differed signifi-
cantly on this variable, both group’s baseline scoring
were low when considering normative data [31]. For
means and standard deviations of the baseline scoring
see Table 1. The recruitment process is depicted in Fig. 1
below.
Design
This was a randomized, parallel group, non-blinded trial
with 1:1 allocation ratio to waiting list control group or
to a twelve session treatment with flotation-REST. The
study was performed in the mid-west part of Sweden
during 2013 to 2015. A two-way split plot design was
performed, where Time with assessments baseline, 4-
weeks in treatment, and after treatment, constituted the
within-subject factor. Group (treatment; waiting list con-
trol) constituted the between-subject factor. The partici-
pants in the treatment group received a 7-week
treatment program of flotation-REST that consisted of
in total 12 treatment sessions (á 45 minutes). The first
treatment session was administered January 2014 and
the last July 2014. A test battery of validated self-report
measures (See Measures) was administered at baseline,
4-weeks in treatment and after treatment. The waiting
list control group was assessed at the corresponding
time periods. After the seven-week treatment period the
waiting list control group were offered a shortened
flotation-REST treatment (four sessions), but no further
data were collected. Follow-up data were collected 6-
months after the end of treatment from the participants
in the treatment group. The last follow-up data was
received January 2015. Estimates of sample size were
determined based on the results of previous studies of
flotation-REST [(e. g.) [21, 23]]. No changes to the
method were done after trial commencement.
Measures
PSWQ—penn state worry questionnaire
The 16-item PSWQ is the most widely used assessment
for pathological worry [32]. The PSWQ has shown good
validity and reliability in both clinical and non-clinical
samples [33, 34]. The PSWQ has also shown to be able
to distinguish GAD-patients from patients with other
psychiatric disorders [35]. The instrument yields a total
score ranging between 16 (minimum) and 80 (max-
imum), with a recommended cut-off score of 45+ indi-
cating GAD [30]. The PSWQ has been translated to
Swedish and validated by Breitholtz and Rondahl [36].
GAD-Q-IV—the generalized anxiety disorder questionnaire
4th edition
The GAD-Q-IV is a 9-item self-report measure assessing
severity of generalized anxiety syndrome (GAD) as
defined by the 4th edition of the Diagnostic and Statis-
tical Manual [1]. The GAD-Q-IV was initially developed
as a screening tool for GAD [37] and in the present
study the measure is used as a continuous variable by
summing the responses and creating a total score ran-
ging from 0 (minimum) to 12 (maximum). Newman et
al. [29] have suggested a cut-off score of 5.7+, yielding
optimal ratio between sensitivity and specificity. This
dimensional scoring system has demonstrated good con-
current and discriminant validity and good test-retest
reliability in non-clinical samples [29]. The GAD-Q-IV
has been translated into Swedish and validated by
Breitholtz and Rondahl [36].
MADRS-S—montgomery-asberg depression rating scale
The 9-item MADRS-S is a well-established Swedish self-
report assessment of depressive symptoms [38]. The
MADRS-S has shown good reliability [39] and corre-
sponds well with clinicians’ ratings [40]. The MADRS-S
yields a total score ranging from 0 (minimum) and 54
(maximum). Each item relates to symptoms of depression,
which is rated from 0 to 6 by respondents regarding how
well it corresponds with their experience of the last three
days. Cut-off values have been established at: 0–6 = no
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Fig. 1 Flow diagram depicting the recruitment process. Template used for the flow diagram was downloaded from http://www.consort-statement.org/
consort-statement/flow-diagram0/
Table 1 Baseline characteristics of participants included in the study
Measure Treatment group (n = 25) Control group (n = 25) Total sample (n = 50)
Age M (SD) 42.71 (12.49) 43.41 (14.57) 43.04 (13.37)
PSWQ 61.88 (11.21) 57.95 (10.29) 60.00 (10.84)
GAD-Q-IV 10.01 (2.20) 9.92 (2.24) 9.87 (2.19)
MADRS-S 24.04 (7.46) 20.77 (7.35) 22.48 (7.51)
PSQI 10.58 (3.92) 9.73 (3.49) 10.17 (3.70)
DERS 101.67 (20.18) 97.64 (20.33) 99.74 (20.13)
MAAS 2.98 (0.65) 3.64 (0.79) 3.29 (0.78)
Sex % (n) % (n) % (n)
Female 72 (18) 68 (17) 70 (35)
Male 28 (7) 32 (8) 30 (15)
Medication
Yes 32 (8) 48 (12) 40 (20)
No 68 (17) 52 (13) 60 (30)
Psychotherapy
Yes 32 (8) 36 (9) 34 (17)
No 68 (17) 64 (16) 66 (33)
Note. PSWQ=Penn State Worry Questionnaire; GAD-Q-IV = Dimensional scoring from the Generalized Anxiety Disorder Questionnaire; MADRS-S =Montgomery-Asberg
Depression Rating Scale; PSQI = Pittsburgh Sleep Quality Index; DERS =Dysfunctional Emotional Regulation Scale – Total mean score; MAAS: Mindful Attention and Awareness
Scale; Medication: intends regular use of anxiolytic and antidepressant drugs (yes/no); Psychotherapy: intends ongoing treatment with psychotherapist (yes/no)
Jonsson and Kjellgren BMC Complementary and Alternative Medicine  (2016) 16:108 Page 4 of 12
depression; 7–19 =mild depression; 20–34 =moderate de-
pression; 34 + = severe depression [38].
PSQI—the Pittsburgh sleep quality index
The PSQI is a 19-item self-report measure assessing sub-
jective sleep quality, and is widely used in both clinical
and non-clinical settings [41]. PSQI have demonstrated
acceptable levels of validity and reliability in both clinical
[42] and non-clinical samples [43]. The instrument mea-
sures sleep disturbance during the previous month. The
PSQI gives a global score ranging from 0 (minimum) to
21 (maximum) that distinguishes between “good” and
“poor” sleepers. A global score of five or higher indicates
poor sleep quality [44]. The PSQI has been translated to
58 languages by the authors of the scale [41] and in the
present study the Swedish version was used.
DERS—the dysfunctional emotional regulation scale
The DERS is a 36-item self-report measure developed by
Gratz and Roemer [45] to assess emotion regulation dif-
ficulties. DERS has shown good reliability and validity
[45] and gives a total score ranging from 36 (minimum)
to 180 (maximum). The scoring was recoded so that
higher scoring indicates greater difficulties in emotion
regulation. In the present study the total score is used as
a general indicator of degree of emotional regulation dif-
ficulties. The instrument has been translated into Swed-
ish by Friberg [46] and validated with similar
psychometric properties as the English version.
MAAS—the mindful attention awareness scale
The MAAS is a 15-item self-report measure of trait
mindfulness (Brown and Ryan [31], and has been the
most empirically tested measure of mindfulness [47].
The MAAS assesses the level of open and receptive
attention to and awareness of ongoing experience.
MAAS scores can range from 1 to 6. Higher scores indi-
cate greater mindfulness. Pilot-studies with the Swedish
version of MAAS have been carried out, indicating the
instruments applicability for assessing trait mindfulness
after translation [48].
EDN—the experienced deviation from normal state scale
The EDN is a Swedish 29-item self-report measure spe-
cifically designed to be used in flotation-REST experi-
ments, and assess degree of relaxation and deviation
from normal state experienced during the flotation ses-
sion [24]. The items consist of statements such as “I
could see images clearly”, “It felt like I was about to fall
asleep” and “I felt a deep peace within me”, which were
graded on VAS-scales ranging from 0 to 100 on how
well they corresponded to the experience during the
flotation-REST session. The EDN yields a total score by
averaging the scoring from the 29 items. In earlier
studies on flotation-REST [20, 49] in which the EDN has
been used, Cronbachs’s alpha has been measured to
0.91–0.97, suggesting good reliability. A score of 30 on
EDN at the first flotation session, and a score of 40 at
the subsequent flotation sessions, is viewed as an indica-
tion of typical treatment response [24], and can be com-
pared to resting on a bed in a dark quiet room which in
general gives score of 15 [50].
Background information
Background information was assessed using a self-
constructed questionnaire which contained questions
regarding age, gender, as well as questions related to the
exclusion criteria’s. In addition, other forms of ongoing
therapeutic treatment were assessed by questions regard-
ing what type of medication used, dosage, as well as if the
participant received psychotherapeutic treatment, and if
so, what type and to what extent they were received.
Flotation tanks
Flotation-tanks measuring 270 cm x 150 cm x 130 cm
were used. The tanks were filled with water saturated
with Epsom salt (magnesium sulphate) approximately
0.3 m in depth. The water temperature was maintained
at a temperature of 35° Celsius. The tanks were insulated
to keep out sound and light, and earplugs were used to
further minimize sensory input. The tanks were situated
in quiet rooms that are locked from the inside, but can
be opened from the outside by the floating laboratory
staff. Shower and toilet could be accessed in the floating
rooms. The participants were instructed to shower
before and after the floating session. Ventilation and
light could be controlled by the participants from inside
the tanks. The participants were instructed to keep the
lights out in the tank if possible. Also an alarm button
could be pushed from inside the tank to alert the staff in
the laboratory if needed. This button was not used by
any of the participants.
Flotation-REST intervention
The intervention for the treatment group consisted of
12 sessions (á 45 min) of flotation-REST extending over
seven weeks with two sessions a week. One week was
treatment free (fourth week). The main reason for hav-
ing a treatment free week was so that female participants
could plan the timing of their flotation treatments from
the incidence of each menstrual cycle. The participants
had the opportunity to sit down and relax for a while
before and after the flotation-sessions, and the staff in
the laboratory kept conversation with the participants to
a minimum.
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Procedure
Participants signed a written informed consent upon
accepting participation in the study to the effect that
they had received sufficient information about the study,
that they were guaranteed confidentiality, could termin-
ate their participation without giving any specific reason,
and that the data collected could be scientifically ana-
lyzed and published as long as the confidentiality of the
participants were guaranteed. Before signing the in-
formed consent, the floating laboratory at Karlstad Uni-
versity was shown and information about the floating
intervention given. Participants were also informed that
they could continue with ongoing therapeutic treatments
during participation in the study.
Participants then completed the self-report mea-
sures used in the study (see Measures) except for the
EDN scale. After checking that the participants met
the inclusion and no exclusion criteria for the study,
participants were randomized to either treatment or
waiting list control condition. Participants in the wait-
ing list control group were informed that they were
entitled to a shortened treatment program (four float-
ing sessions) after they completed the post-treatment
assessments, and two additional visits to the labora-
tory were booked four and seven weeks later for
further assessments. For the participants in the treat-
ment group the two initial floating sessions were
booked for the coming week. During the floating
sessions, staffs were present in the laboratory and
could be alerted with an alarm button inside the
floating tank. The EDN scale was administered for
the treatment group after their first floating session,
followed by four weeks in treatment and post-
treatment assessments (after a flotation session). Four
weeks in- and post-treatment the self-report mea-
sures, except background data and EDN, were filled
out again by all the participants. For the treatment
group this was done in adjunction to a floating
session (before), and for the waiting list control group
this was done at the booked visits to the laboratory.
Six months after completed treatment follow-up data,
consisting of all the self-report measures at post-
treatment except for EDN, was collected by mail cor-
respondence with the participants in the treatment
group. Additional data were also collected and are
presented elsewhere (Jonsson & Kjellgren: A phenom-
enological perspective on the experience of undergo-
ing flotation-REST treatment while having generalized
anxiety disorder, in preperation).
Ethics
The protocol for this study was approved by the Ethical
Board on Experimentation on Human Subjects in Upp-
sala, Sweden (Dnr 2013/357). The study is registered in
the Australian New Zealand Clinical Trial Registry
(ACTRN12613001105730). Date of registration: 09/10/
2015.
Data analysis
A two-way mixed Pillais’ MANOVA was used, where
Time with assessments before (Baseline), four weeks in
treatment (Mid), and after treatment (Post-treatment)
constituted the within group factor and where Group
(Treatment, Waiting list control) constituted the
between group factor. The primary outcome was the
participants’ level of GAD-symptomatology (GAD-Q-4),
and the secondary outcomes were pathological worry
(PSWQ), difficulties in emotional regulation (DERS),
Mindfulness (MAAS), sleep difficulties (PSQI), and
depression (MADRS-S). In addition, independent sample
t-tests were performed comparing the groups scoring on
the dependent variables at post-treatment. For the treat-
ment group a one-way ANOVA was conducted for the
scoring on EDN for the three time periods (Baseline,
Mid, Post-treatment). Paired sample t-test was also
carried out comparing participants scoring on the
dependent variables at post-treatment with 6-months
follow-up scoring. This was only assessed for the treat-
ment group to assess any lasting effects of the treatment.
Chi-Square goodness of fit tests was conducted, compar-
ing the groups in regard to received psychotherapy and
the use of anxiolytic, antidepressant, as well as sleep
medication at baseline and post-treatment. In addition,
the criteria for “clinical significant improvement” as
defined by Jacobson, Follette and Revenstor [51] were
used to determine the precision of the treatment effects.
This implies that treated individuals must, in addition to
showing a statistically reliable change, fall within the
range of a normal group, at post-treatment assessment,
as indicated by for an example established cut-off values
for a specific self-report measure. Clinical significant
change was assessed for PSWQ, GAD-Q-IV, MADRS-S
and PSQI. See Measures for the cut-off values used for
these assessments.
Results
The analysis yielded significant main effects for Time [F(12,
33) = 5.69, p < 0.001, ηp
2 = .67] and Group [F(6, 39) = 2.44, p
= .042, ηp
2 = .27]. There was also a significant Time x
Group interaction effect [F(12, 33) = 3,87, p = .001, ηp
2 = .58).
The results from the univariate F-tests are presented
below. For means and standard deviations, see Table 2.
Primary outcome
GAD-symptomatology
The analysis indicated significant difference for Time
[F(2,88) = 8.79, p < .001, ηp
2 = .167], and the descriptive
data showed that GAD-symptomatology decreased.
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There was also a significant Time x Group interaction
effect [F(2,88) = 2.93, p < .001, ηp
2 = .062], and further ana-
lyses (paired-samples t-tests, 5 % level) showed that the
GAD-symptomatology was significantly reduced for the
treatment group (t(23) = 4.47, p < .001), but not for the
waiting list control group (t(21) = 0.98, p > .05), when
comparing baseline to post-treatment scoring. Subse-
quent pairwise comparisons (5 % level) of Time for
both groups also indicated a significant decrease for
the treatment group when comparing baseline to mid
scoring (p < .05). No other comparisons for Time were
significant (ps > .05).
Comparing the groups at post-treatment (independent
sample t-test, 5 % level) showed that the the treatment
group had significantly lower GAD- symptomatology then
the waiting list control group (t(44) = − 2.27, p < 0.05).
Regarding clinical significant change, nine participants
(37 %) in the treatment group, and three participants
(14 %) in the waiting list control group, scored below the
suggest cut-off value indicating full remission of GAD at
post-treatment. Figure 2 below illustrate changes in GAD-
symptomatology for the two groups over time.
Pathological worry
The analysis indicated significant difference for Time
[F(2,88) = 16.28, p < .001, ηp
2 = .27], and the descriptive
data showed that pathological worry decreased. There
was also a significant Time x Group interaction effect
[F(2,88) = 4.05, p < 0.05, ηp
2 = .084], and further analyses
(paired-samples t-tests, 5 % level) showed that patho-
logical worry was significantly reduced for both the
treatment group (t(23) = 5.77, p < .001), and for the wait-
ing list control group (t(21) = 2.15, p < .05), when compar-
ing baseline to post-treatment scoring. Subsequent
pairwise comparisons (5 % level) of Time for both
groups also indicated a significant decrease for the
treatment group when comparing baseline to mid scor-
ing, and when comparing mid to post-treatment
scoring (ps < .05). No other comparisons for Time were
significant (ps > .05).
Comparing the groups at post-treatment (independent
sample t-test, 5 % level) showed that the groups did not
significantly differ (t(44) = − 2.27, p < .05). Regarding clin-
ical significant change, three participants (12 %) in the
treatment group, and four participants (18 %) in the
waiting list control group, scored below the suggest cut-
off value indicating full remission of GAD at post-
treatment.
Difficulties in emotional regulation
The analyses indicated significant difference for Time
[F(2,88) = 7.73, p < .001, ηp
2 = .15], and the descriptive data
showed that difficulties in emotional regulation de-
creased. The analyses also yielded a significant Time x
Group interaction effect [F(2,88) = 8.61, p < .001, ηp
2 = .16],
and further analyses (paired-samples t-tests, 5 % level)
showed that difficulties in emotional regulation was
significantly reduced for the treatment group (t(23) =
4.01, p < .01), but not for the waiting list control group
(t(21) = 0.00, p > .05), when comparing baseline to post-
treatment scoring. Subsequent pairwise comparisons
(5 % level) of Time for both groups also indicated a
significant decrease for the treatment group when
comparing baseline to mid scoring, (p < .05). No other
comparisons for Time were significant (ps > .05).
Comparing the groups scoring at post-treatment (in-
dependent sample t-test, 5 % level) showed that the
treatment group had significantly lesser difficulties in
emotional regulation than the waiting list control group
(t(44) = − 2.22, p < .05).
Mindfulness
There was no significant effect for Time [F(2,88) = 1.39,
p > .05, ηp
2 = .031], but there was significant Time x Group
interaction effect [F(2,88) = 9.28, p < .001, ηp
2 = .174]. Further
analyses (paired-samples t-tests, 5 % level) showed that
Table 2 Means (standard deviations) for treatment outcomes divided by time and group
Treatment group (n = 24) Control group (n = 22)
Measure Baseline Mid After Baseline Mid After
MADRS-S 24.04 (7.46) 13.38 (5.80) 10.25 (7.56) 20.77 (7.46) 21.09 (6.67) 19.09 (7.98)
PSWQ 61.88 (11.21) 56.21 (13.93) 52.67 (12.25) 57.95 (10.29) 56.91 (10.54) 54.68 (11.47)
GAD-Q-IV 10.01 (2.20) 7.75 (3.88) 7.07 (3.02) 9.92 (2.24) 9.07 (2.88) 9.22 (3.38)
PSQI 10.58 (3.92) 6.88 (4.05) 5.71 (3.32) 9.73 (3.49) 9.18 (3.78) 8.68 (4.08)
DERS 99.67 (20.18) 85.63 (22.55) 83.04 (22.86) 97.64 (20.33) 98.86 (21.88) 97.64 (21.43)
MAAS 2.98 (0.65) 3.37 (0.79) 3.64 (1.06) 3.64 (1.06) 3.45 (0.72) 3.35 (0.81)
EDN 31.59 (15.43) 45.48 (15.43) 44.05 (16.25)
Note. PSWQ Penn State Worry Questionnaire, GAD-Q-IV Dimensional scoring from the Generalized Anxiety Disorder Questionnaire, MADRS-S Montgomery-Asberg
Depression Rating Scale, PSQI Pittsburgh Sleep Quality Index, DERS Dysfunctional Emotional Regulation Scale – Total mean score, MAAS Mindful Attention and
Awareness Scale, EDN = Experienced deviation from normal state scale; Baseline = Before treatment; Mid = 4 weeks in treatment; After = Post-treatment
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mindfulness significantly increased for the treatment
group (t(23) = − 3.00, p < .01), and significantly decreased
for the control group (t(21) = 2.36, p < .05), when compar-
ing baseline to post-treatment scoring. Subsequent pair-
wise comparisons (5 % level) of Time for both groups,
indicated a significant increase for the treatment group
when comparing baseline to mid scoring (p < .05). No
other comparisons for Time were significant (ps > .05).
Comparing the groups scoring at post-treatment (in-
dependent sample t-test, 5 % level) showed that the
groups did not significantly differ (t(44) = 1.01, p > .05).
Sleep difficulties
The analysis indicated significant difference for Time
[F(2,88) = 19.52, p < .001, ηp
2 = .30], and the descriptive data
showed that sleep difficulties decreased. There was also a
significant Time x Group interaction effect [F(2,88) = 8.76,
p < .001, ηp
2 = .16], and further analyses (paired-samples t-
tests, 5 % level) showed that sleep difficulties was sig-
nificantly reduced for the treatment group (t(23) = 5.87,
p < .001), but not for the control group (t(21) = 2.13,
p > .05), when comparing baseline to post-treatment
scoring. Additional pairwise comparisons (5 % level) of
Time for both groups, indicated a significant decrease
for the treatment group when comparing baseline to
mid scoring (p < .05). No other comparisons for Time
were significant (ps > .05).
Comparing the groups at post-treatment (independent
sample t-test, 5 % level) showed that the treatment group
had significantly lesser sleep difficulties than the waiting
list control group (t(44) = − 2.71, p < .01). Regarding clinical
significant change, 13 participants (43 %) in the treatment
group, and six participants (27 %) in the waiting list con-
trol group, scored below the suggest cut-off value indicat-
ing a “good sleeper” at post-treatment.
Depression
The analysis indicated significant difference for Time
[F(2,88) = 31.60, p < 0.001, ηp
2 = .32], and the descriptive data
showed that the level of depression decreased. The ana-
lysis also yielded a significant Time x Group interaction
effect [F(2,88) = 22.77, p < 0.001, ηp
2 = .34], and further ana-
lyses (paired-samples t-tests, 5 % level) showed that level
Fig. 2 Bar-chart illustrating means for the scoring on GAD-Q-IV, with associated 95 % confidence interval, for treatment and control group at baseline,
4 weeks in treatment, and post-treatment
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of depression was significantly reduced for the treatment
group (t(23) = 7.24, p < .001), but not for the waiting list con-
trol group (t(21) = 1.12, p > .05), when comparing baseline to
post-treatment scoring. Subsequent pairwise comparisons
(5 % level) of Time also indicated a significant decrease for
the treatment group when comparing baseline to mid scor-
ing, and when comparing mid to post-treatment scoring
(ps < .05). No other comparisons of Time were significant
(ps > .05).
When comparing the groups at post-treatment (inde-
pendent sample t-test, 5 % level), it was found that the
treatment group had significant lesser depression that
the waiting list control group (t(44) = − 3.85, p < .001).
Regarding clinical significant change, 10 participants
(42 %) in the treatment group, and two participants
(9 %) in the waiting list control group, scored below the
suggest cut-off value indicating a full remission of
depression at post-treatment.
Experienced deviations from normal state
Assessment of deviations from normal state during the
flotation sessions (for the treatment group) indicated a
main effect for Time [F(2,22) = 6.57, p < .05, ηp
2 = .37], with
a significant increase in EDN-scoring from baseline to
mid scoring and from baseline to post-treatment scoring
(ps < .05). There was no significant effect when compar-
ing mid to post-treatment scoring (p > .05), indicating
that most changes on this variable occurred in the first
four weeks of treatment and then was maintained at this
level for the rest of treatment (see Table 2).
Follow-up data
In total nineteen (n = 19) from the treatment group
returned the follow-up assessments by mail. Results indi-
cated no significant difference (ps > .05) for GAD- symp-
tomatology, pathological worry, sleep difficulties, emotion
regulation difficulties or mindfulness when comparing
post-treatment to follow-up scorings (See Table 3),
indicating that the effects from treatment were maintained
at 6-month follow-up. For depression, the scoring was
higher at follow-up compared to post-treatment, and this
difference was significant (t(18) = −2.90, p < .05), indicating
that treatments effect on depression was not maintained
at 6-month follow-up.
Medication and psychotherapy
Chi-square goodness of fit test (5 %) indicated no signifi-
cant differences when comparing the groups in regard to
received psychotherapy and the use of anxiolytic, anti-
depressant, as well as sleep medication at baseline and
post-treatment (see Table 4). One participant in the con-
trol group, but none in the treatment group, increased the
dosage of anxiolytic medication during the course of the
study. In addition, two participants in the treatment group
decreased their dosage of sleep medication. Psychotherapy
consisted of CBT,except for one participant in the control
group and two participants in the treatment group that
received unspecified counseling..Participants who had on-
going psychotherapy during the study met with their ther-
apist one time a week.
Discussion
The main goal of the present study was to do an initial
evaluation of flotation-REST as a treatment of GAD.
The sample used was screened with self-report measures
extensively used to detect GAD in both clinical and
non-clinical populations [29, 30]. The main findings
were that flotation-REST significantly reduced both the
general GAD-symptomatology, as well as several symp-
toms associated with the disorder, such as difficulties in
emotional regulation, sleep difficulties and depression,
while having ambiguous or non-existent effect on level
of pathological worry and mindfulness. In addition, all
improved outcome variables at post-treatment, except
for depression, were maintained at 6-month follow-up
assessments.
Considering that GAD has been considered a treatment
resistant disorder [16, 52] it is interesting that flotation-
REST significantly improved GAD-symptomatology (ηp
2
= .062), in which 37 % in the treatment group reached
full remission at post-treatment (waiting list control:
14 %). Results also showed that some factors known to
play an important part in maintaining GAD (patho-
logical worry and low mindfulness) were not affected
by the treatment. A possible interpretation of these
results might be that treatment mainly affects physio-
logical factors in the GAD-symptomatology, such as
restlessness, fatigue and muscle tensions, thus explain-
ing the reduction of the general GAD-symptomatology,
while the core characteristic of GAD, the pathological
worry, is left marginally affected. This interpretation is
also supported by earlier research on flotation-REST
Table 3 Means (standard deviations) for assessed variables at
post-treatment and at 6-month follow-up. Treatment group only
Measure Post-treatment (n = 24) Follow-up (n = 19)
GAD-Q-IV 7.07 (3.02) 6.65 (4.17)
PSWQ 52.67 (12.25) 53.06 (12.69)
DERS 83.04 (22.86) 85.12 (24.74)
MADRS-S 10.25 (7.56) 13.88 (8.10)a
PSQI 5.71 (3.32) 7.59 (3.95)
MAAS 3.64 (1.06) 3.61 (1.11)
Note. GAD-Q-IV Dimensional scoring from the Generalized Anxiety Disorder
Questionnaire, PSWQ Penn State Worry Questionnaire, DERS Dysfunctional
Emotional Regulation Scale – Total mean score; MADRS-S Montgomery-Asberg
Depression Rating Scale, PSQI Pittsburgh Sleep Quality Index, MAAS Mindful
Attention and Awareness Scale
aSignificant at the 0.05 level
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which has shown that the most robust effects from
flotation-REST are relaxation [18] and reduction of
muscle tension pains [(e. g.) [24]]. Taken together this
implies that additional treatment is needed to reach full
remission of GAD-symptomatology by floating.
However, there was a convincing beneficial effect of
flotation treatment on difficulties in emotional regulation
(ηp
2 = .16), indicating that the awareness of emotions in-
creased, and that the treatment enabled individuals with
GAD to better understand and regulate their emotional
responses. This is an important finding considering earlier
laboratory studies, reporting that individuals who met the
criteria for GAD by self-reports measures had higher
levels of intensity of emotional experience than control
individuals, and in addition exhibited marked difficulties
in their capacity to identify, describe, and accept emo-
tional experience [53]. Emotion regulation training has
been proposed to be a potentially valuable addition to
existing treatment protocols for GAD [54], in the light of
this, flotation-REST might be an asset in the treatment of
GAD, targeting this aspect of difficulties associated with
the disorder.
The results also indicated that the flotation treatment
had a strong beneficial effect (ηp
2 = .16) on sleep difficulties,
in which 43 % of the participants in the treatment condi-
tion were “good sleepers” at post-treatment (waiting list
control: 27 %). Co-existence of sleep difficulties and
anxiety has been extensively reported in previous stud-
ies [(e. g.) [55]], and approximately half of individuals
diagnosed with GAD report having difficulties with
sleeping [56]. This underlines the importance of this
finding, and suggests that individuals with GAD might
benefit from flotation-REST treatment by improving
their sleep.
The improvement of sleep could also have contributed
to other beneficial effects, such as the lowering of de-
pression, which was the strongest effect from treatment
(ηp
2 = .34), and where 42 % of the participants in the
treatment group reached full remission at post-
treatment (waiting list control: 9 %), especially when
considering earlier studies which have suggested that
sleep difficulties could trigger depression and other
forms of psychiatric diseases (e. g. [57]). The reduction
of depression is also in line with earlier research on
flotation-REST which has repeatedly demonstrated this
effect for various populations suffering from stress
related disorders [(e. g.) [20, 21]]. The observed im-
provements of depression at post-treatment were not
maintained at 6-months follow-up, which might indicate
that additional booster session is necessary to make this
effect of treatment persist over time.
Regarding treatments effect on mindfulness, the
groups did not significantly differ at post-treatment, des-
pite that results indicated a considerable significant Time
x Group interaction (ηp
2 = .17). The treatment group sig-
nificantly increased their level of mindfulness when
comparing baseline to post-treatment scoring, but since
the groups differed significantly on this variable at base-
line it is hard to draw any firm conclusion about the
treatments effectiveness on this dimension.
The several positive effects of treatment observed in
the present study suggest that individuals with GAD, in
line with what has been confirmed in other flotation-
REST studies on various patient-groups [(e. g.) [19, 23,
24]], experienced the treatment as beneficial. Possible
the deep relaxation that is induced during the flotation
sessions could be a contributing factor to these positive
effects from treatment. This is supported by the scoring
on the EDN-scale, which has been used extensively in
earlier flotation-REST studies [(e. g.) [19, 20]] as an
indirect measure of experienced relaxation during the
flotation sessions. The significant increase over time for
the treatment group on this variable, indicated a normal
treatment response of flotation-REST [(e. g.) [24]].
This study is not without limitations. Even though the
sample was identified with self-report measures that has
been extensively used to identify GAD in both clinical and
non-clinical populations, more research with clinical pop-
ulations is needed to confirm that the findings is
generalizable to GAD patients. The cut-off score used for
the PSWQ could also be regarded as relatively low com-
pared to some studies [(e. g.) [58]], which further under-
lines the importance to conduct studies with clinical
populations to be able to draw any firm conclusions re-
garding the effectiveness of flotation-REST as a treatment
of GAD. There was also a small but significant difference
when comparing the groups scoring of mindfulness at
baseline, although the level is to be considered low for
Table 4 Percentage of participants in each group that received medication and psychotherapy
Variable Control Treatment
Baseline (n = 25) Post (n = 22) Baseline (n = 25) Post (n = 24) follow-up (n = 19)
Psychotherapy 36 % 36 % 28 % 20 % 16 %
Anxiolytics 28 % 22 % 20 % 16 % 16 %
Antidepressants 28 % 22 % 24 % 20 % 10 %
Sleep medication 8 % 9 % 12 % 0 % 5 %
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both groups when considering normative data [31]. This
group difference is still somewhat problematic, especially
since mindfulness is associated with depression and
pathological worry [(e. g.) [59]]. On the other hand, the
scoring on the other assessments at baseline showed sub-
stantial psychological suffering for both groups, including
the dimensions of pathological worry and depression, indi-
cating that the difference on the mindfulness dimension at
baseline did not have a significant impact on the other
dependent variables. Furthermore, a sizeable proportion
of the the participants received uncontrolled medication
and/or psychotherapy. In addition, the CBT interventions
received could possible differ in quality, both in regard of
the competence of the therapist, and in regard of potential
differences in what CBT techniques that were emphasized
during these treatments. Although it can not be ruled out
that the groups differed in regard to how other forms of
received treatment impacted the dependent variables, the
effects from these confounding variables should have been
addressed by the applied randomization to the sample. That
randomization worked out efficiently is also indicated by
the chi-square test at baseline and post-treatment, which
showed that the groups did not significantly differ in regard
to received psychotherapeutic and psychopharmacological
treatments. In addition, although no statistical difference
was found in regard to received psychopharmacological
treatment, the use of medications was somewhat higher for
the control group at baseline.
Despite these limitations, the present study provides
some initial data which could guide further research in the
field. Considering these results, as well as that no negative
side effects has been associated with the method either in
present or other studies, further research should try to es-
tablish that the current findings is applicable to patients
with GAD, by conducting randomized clinical trials with
active control condition, and by further enhance the study
design by for an example blinding the study personnel. It
could also be of interest to study flotation-REST combined
with a psychotherapeutic intervention, which in earlier
pilot-studies [(e. g.) [27, 28] has been reported to be a
combination which makes the treatment process more ef-
fective. Furthermore, flotation-REST should be explored
as a complementary intervention of other types of mood
and anxiety disorders, especially those in which emotional
regulation difficulties, sleep difficulties and depression are
central issues.
Conclusions
The present study is the first to evaluate flotation-REST
primarily as an intervention for GAD.
The findings suggest that flotation-REST has potential
as a complementary treatment modality alongside existing
treatment protocols for GAD, and that more studies
exploring this novel approach could be a fruitful endeavor
for advancing existing treatments of GAD. Considering
the results, further research should focus on how the
treatment could best be implemented as an intervention
for improving sleep, mood and emotion regulation diffi-
culties in individuals with GAD.
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